亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Engineering Induced Pluripotent Stem Cells for COPD Therapy

總結
Researchers at Oklahoma State havedeveloped a method that can induce 90% differentiation of iPSCs or MSCs intoAECs (type II) under stimulation of proper growth factors and growing on anappropriate matrix. These cells expressed type II cell markers surfactantprotein C and ABCA3, secrete lung surfactant in response to lung surfactantsecretagogues and trans-differentiate into type I AECs. Inaddition, the researchers have demonstrated that the AEC cells attenuated lung injuryin a mouse model of COPD. The potential uses for these cells includecellular-based therapies, drug screening, disease modeling and pulmonary research.
技術優勢
·        90% differentiation efficiency of iPSCs or MSCs into AECs
技術應用
·        Therapeutic for pulmonary diseases, including COPD·        Drug discovery·        Disease modeling·        Pulmonary research·        Stem cell research
詳細技術說明
None
*Abstract
None
*Background
The discovery of mesenchymal stem cells(MSCs) and induced pluripotent stem cells (iPSCs) have resulted in a plethoraof opportunities to produce tissue-specific cell types for disease modeling, drugscreening and treatments for diseases. For pulmonary diseases such as COPD,stem cells have been a proposed strategy to repair damaged lungs. However, thesestudies have yielded controversial results. Additional research hasdemonstrated that transplantation of alveolar epithelial cells (AECs) holdgreat promise to repair damaged lungs for pulmonary diseases, including COPD.However, the conversion of stem cells to AECs has proven to be difficult withextremely low differentiation percentages. This major barrier has hamperedimplementation of AEC cells for use in therapies, disease modeling, drugscreening and other areas of pulmonary research. Given that over 300 milliondollars of NIH money is awarded each year to pulmonary researchers, and thatthe pulmonary drug and drug delivery market is estimated to reach 43.9 billiondollars by 2018, developing methods to efficiently produce AECs would bebeneficial.
*Stage of Development
These cells are developed and ready tobe used
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備